Stivarga (regorafenib) — CareFirst (Caremark)

Initial criteria

• Requested for subsequent treatment of advanced, recurrent/metastatic, or inoperable uterine sarcoma as a single agent

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

12 months